Veridex Pulls GeneSearch From US, European Markets Due to 'Low Adoption'

Relatively high start-up costs, a tendency toward false positives, and limited availability could have doomed the test from the beginning.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories